• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bioventus Inc.

    3/11/25 7:45:46 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email
    S-8 1 bvsmarch2025s-8.htm S-8 Document

    As filed with the Securities and Exchange Commission on March 11, 2025
    Registration No. 333-
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
    Bioventus Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware 81-0980861
    (State or other jurisdiction
    of incorporation or organization)
     
    (I.R.S. Employer
    Identification Number)
    4721 Emperor Boulevard, Suite 100
    Durham, North Carolina 27703
    (Address of principal executive offices) (Zip code)
    Bioventus Inc. 2021 Incentive Award Plan
    Bioventus Inc. 2021 Employee Stock Purchase Plan
    (Full title of the plans)
     
    Robert E. Claypoole
    President and Chief Executive Officer
    Bioventus Inc.
    4721 Emperor Boulevard, Suite 100
    Durham, North Carolina 27703
    (919) 474-6700
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)
    With copies to:
    Donald Reynolds, Esq.
    Wyrick Robbins Yates & Ponton LLP
    4101 Lake Boone Trail, Suite 300
    Raleigh, North Carolina 27607
    Telephone: (919) 781-4000
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    ☐
    Accelerated filer
    ☒
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☒
    Emerging growth company
    ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.  ☒




    EXPLANATORY NOTE
    Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 is being filed for the purpose of registering an additional 3,669,529 shares of Bioventus Inc.’s (the “Registrant”) Class A common stock to be issued pursuant to the Bioventus Inc. 2021 Incentive Award Plan (the “2021 Plan”) and an additional 657,583 shares of the Registrant’s Class A common stock to be issued pursuant to the Bioventus Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”) and for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.
    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8
    The contents of the Registration Statements on Form S-8 (File No. 333-252981, File No. 333-263496, File No. 333-271310, and File No. 333-278100), filed with the Securities and Exchange Commission on February 11, 2021, March 11, 2022, April 18, 2023, and March 20, 2024, respectively, relating to the 2021 Plan and the 2021 ESPP, as amended, or as modified or superseded pursuant to Rule 412 under the Securities Act of 1933, as amended, are incorporated herein by reference.
    Part II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 8. Exhibits
    Exhibit no.
    Description
      
    4.1
    Amended and Restated Certificate of Incorporation of Bioventus Inc. (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-37844) filed on February 17, 2021).
    4.2
    Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bioventus Inc. (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-37844) filed on June 17, 2024).
    4.3
    Second Amended and Restated Bylaws of Bioventus Inc. (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K (File No. 001-37844) filed on June 17, 2024).
    5.1*
    Opinion of Wyrick Robbins Yates & Ponton LLP.
      
    23.1*
    Consent of Grant Thornton, Independent Registered Public Accounting Firm.
     
    23.2*
    Consent of Wyrick Robbins Yates & Ponton LLP (included in Exhibit 5.1).
      
    24.1*
    Power of Attorney (included on signature page).
    99.1
    Bioventus Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No 001-37844), filed on August 12, 2022).
      
    99.2
    Bioventus Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.44 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-252238), filed on February 4, 2021).
      
    107.1*
    Filing Fee Table.
    * Filed herewith
    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on March 11, 2025.
    BIOVENTUS INC.
    Date: March 11, 2025By:/s/ Robert E. Claypoole
    Robert E. Claypoole
    President, Chief Executive Officer and Director (Principal Executive Officer)





    POWER OF ATTORNEY
    Each person whose signature appears below hereby constitutes and appoints Robert E. Claypoole and Mark L. Singleton, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
    Name
    Date
    Title
    /s/ Robert E. ClaypooleMarch 11, 2025President, Chief Executive Officer and Director
    (Principal Executive Officer)
    Robert E. Claypoole
      
    /s/ Mark L. SingletonMarch 11, 2025Senior Vice President and Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)
    Mark L. Singleton
    /s/ William A. Hawkins IIIMarch 11, 2025Chairman
    William A. Hawkins III
    /s/ John A. BartholdsonMarch 11, 2025Director
    John A. Bartholdson
    /s/ Patrick J. Beyer
    March 11, 2025Director
    Patrick J. Beyer
    /s/ Philip G. CowdyMarch 11, 2025Director
    Philip G. Cowdy
    /s/ Mary Kay LadoneMarch 11, 2025Director
    Mary Kay Ladone
    /s/ Michelle McMurry-HeathMarch 11, 2025Director
    Michelle McMurry-Heath
    /s/ Guido J. NeelsMarch 11, 2025Director
    Guido J. Neels
    /s/ Guy P. NohraMarch 11, 2025Director
    Guy P. Nohra
    /s/ Susan M. StalneckerMarch 11, 2025Director
    Susan M. Stalnecker
    /s/ Martin P. SutterMarch 11, 2025Director
    Martin P. Sutter

    Get the next $BVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    2/9/2026$13.00Outperform
    Barrington Research
    7/7/2025$12.00Overweight
    Cantor Fitzgerald
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    More analyst ratings

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Claypoole Robert E covered exercise/tax liability with 41,717 shares and converted options into 93,750 shares, increasing direct ownership by 80% to 116,997 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    1/13/26 5:30:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Director Nohra Guy P sold $75,658 worth of shares (10,000 units at $7.57), decreasing direct ownership by 8% to 116,610 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    12/8/25 5:02:29 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    New insider Dhankhar Ajay claimed no ownership of stock in the company (SEC Form 3)

    3 - Bioventus Inc. (0001665988) (Issuer)

    11/25/25 6:06:11 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BVS
    SEC Filings

    View All

    Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available for replay until February 14, 2026. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active

    1/6/26 7:30:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference

    DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make

    11/25/25 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

    DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

    10/28/25 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    8/20/24 6:16:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on Bioventus with a new price target

    Cantor Fitzgerald initiated coverage of Bioventus with a rating of Overweight and set a new price target of $12.00

    7/7/25 8:17:29 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus upgraded by Analyst with a new price target

    Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

    12/17/24 7:32:13 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Bioventus Inc.

    144 - Bioventus Inc. (0001665988) (Subject)

    12/4/25 1:54:35 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Inc. filed SEC Form 8-K: Leadership Update

    8-K - Bioventus Inc. (0001665988) (Filer)

    11/17/25 5:04:41 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Bioventus Inc.

    10-Q - Bioventus Inc. (0001665988) (Filer)

    11/4/25 7:39:06 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bioventus Appoints Mark Singleton as Chief Financial Officer

    DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

    2/28/22 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Appoints Michelle McMurry-Heath to Board of Directors

    DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

    12/21/21 9:25:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Financials

    Live finance-specific insights

    View All

    Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

    DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

    10/28/25 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

    DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-800-715-9871 and refer either to the Bioventus Inc. Conference Call or the conference ID 1859022. A live webcast of the call and accompanying materials will also be provided on the "Investo

    7/29/25 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

    DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

    4/28/25 8:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    11/8/24 9:13:26 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    7/15/24 5:15:58 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    2/14/24 4:51:41 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care